ERIC Number: ED192908
Record Type: RIE
Publication Date: 1980-Feb
Reference Count: 0
Infant Formula: Our Children Need Better Protection. Report Together with Dissenting Views by the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce (H.R., 96th Congress, Second Session).
Congress of the U. S., Washington, DC. House Committee on Interstate and Foreign Commerce.
This report of the Subcommittee on Oversight and Investigation focuses on issues raised by the marketing of commercially prepared infant formulas that were nutritionally deficient. In this context, the report examines the scope of FDA authority to protect the public and the manner in which the FDA carries out its responsibilities with respect to product recalls. Additionally, the report reviews existing standards and regulations for infant formulas, and reports findings of an investigation into the manner in which one manufacturer, Syntex Laboratories Inc. of Palo Alto, California, complied with these regulations. This investigation revealed that over 100 infants became ill, some severely so, as a result of having been dependent on the formula for a long period of time. In evaluating the actions of the FDA and this manufacturer, the subcommittee found that little had been done to minimize or prevent this affair. Consequently, it was recommended: (1) that congress enact legislation to create a separate category of food known as infant formula; (2) that infant formula contain all nutrients recognized as essential; (3) that the formula be tested at critical times for nutritional adequacy; and (4) that the FDA be given the ability to inspect records of infant formula manufacturers. (Author/MP)
Descriptors: Case Studies, Consumer Protection, Federal Regulation, Food Standards, Hearings, Infants, Legislation, Manufacturing, Needs Assessment, Nutrition
Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20408 (no price quoted).
Publication Type: Reports - Evaluative; Legal/Legislative/Regulatory Materials
Education Level: N/A
Authoring Institution: Congress of the U. S., Washington, DC. House Committee on Interstate and Foreign Commerce.
Identifiers: Food and Drug Administration; Infant Formula